What Does Cerus Corporation Do?

Total employees657
HeadquartersConcord
Founded1991

Cerus Corporation is a biomedical products company dedicated to safeguarding the world's blood supply. Their flagship product, the INTERCEPT Blood System, is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites in donated blood components (platelets, plasma, and red blood cells under investigation). Cerus focuses on providing solutions for blood centers and hospitals to enhance the safety and availability of blood transfusions for patients worldwide, with a mission to make blood transfusions the safest medical intervention.

Where Is Cerus Corporation's Headquarters?

Cerus Corporation officeCerus Corporation officeCerus Corporation officeCerus Corporation office
*Images sourced via web search. Rights belong to original owners

HQ Function

Serves as the primary center for corporate leadership, research and development (R&D), strategic planning, global operations management, and administrative functions.

Notable Features:

The Concord facility likely houses advanced research laboratories for biomedical product development, quality control, and testing, alongside modern office spaces designed to foster collaboration and innovation.

Work Culture:

Cerus fosters a science-driven, mission-oriented work culture. Employees are typically passionate about public health, innovation in blood safety, and making a significant impact on patient care globally. The environment emphasizes collaboration, integrity, and a commitment to quality.

HQ Significance:

The Concord headquarters is crucial for Cerus's global strategy, driving innovation in its INTERCEPT Blood System technology, managing clinical trials, and overseeing the commercialization and distribution of its products worldwide.

Values Reflected in HQ: The headquarters' operations and design likely reflect Cerus's core values: patient focus, scientific excellence, integrity, innovation, and a commitment to global public health.

Location:

Cerus Corporation has a significant global presence, with its INTERCEPT Blood System used by blood centers and hospitals in numerous countries. Key functions supported globally include sales and marketing, clinical support and education, product distribution, regulatory affairs, and post-market surveillance. While direct operations are prominent in North America and Europe, Cerus also works with a network of distributors to extend its reach to other regions, including Asia-Pacific and Latin America, aiming to make its blood safety technology a worldwide standard.

Street Address:

1220 Concord Avenue

City:

Concord

State/Province:

California

Country:

USA

Where Else Does Cerus Corporation Operate Around the World?

Amersfoort, Netherlands

Address: Stationsplein 13 N, 3818 LE Amersfoort, Netherlands

To drive adoption of the INTERCEPT Blood System across the EMEA region, provide regional customer and technical support, and navigate local regulatory landscapes to ensure product availability.

Buying Intent Signals for Cerus Corporation

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Cerus Corporation? Meet the Executive Team

As of April 2025, Cerus Corporation' leadership includes:

William M. Greenman - President and Chief Executive Officer
Vivek K. Jayaraman - Chief Operating Officer
Kevin D. Green - Chief Financial Officer
Dr. Richard J. Benjamin - Chief Medical Officer
Chrystal Menard - Chief Legal Officer and General Counsel
Carol Moore - Chief Quality and Regulatory Affairs Officer

Who's Investing in Cerus Corporation?

Cerus Corporation has been backed by several prominent investors over the years, including:

BlackRock Inc.
The Vanguard Group, Inc.
Perceptive Advisors LLC
Renaissance Technologies LLC
Baker Bros. Advisors LP
State Street Corporation

What Leadership Changes Has Cerus Corporation Seen Recently?

Hire1
Exits1

In the past 12 months, Cerus Corporation has made strategic adjustments to its financial leadership team, notably appointing a new Chief Accounting Officer.

Departures

Lisa L. Bouldin, Lisa L. Bouldin transitioned from her role as Chief Accounting Officer.

New Appointments:

Hua (Judy) Wang, Hua (Judy) Wang appointed as new Chief Accounting Officer (Principal Accounting Officer).

What Technology (Tech Stack) Is Used byCerus Corporation?

Discover the tools Cerus Corporation uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Cerus Corporation Email Formats and Examples

Cerus Corporation commonly uses email formats based on employee names, typically combining the first initial and last name. Variations might exist, but this is a frequently observed pattern.

[first_initial][last]@cerus.com

Format

jdoe@cerus.com

Example

90%

Success rate

What's the Latest News About Cerus Corporation?

Cerus Corporation Investor Relations • May 2, 2024

Cerus Corporation Reports First Quarter 2024 Financial Results

Cerus announced its financial results for the first quarter ended March 31, 2024, highlighting product revenue of $38.5 million and providing updates on its development pipeline, including the INTERCEPT Fibrinogen Complex and Red Blood Cell programs....more

Cerus Corporation Investor Relations • May 8, 2024

Cerus Corporation to Present at BofA Securities 2024 Health Care Conference

Cerus Corporation announced that its management team would present at the BofA Securities 2024 Health Care Conference on May 15, 2024, offering an overview of the company's business and strategic initiatives to the investment community....more

Cerus Corporation Investor Relations • March 12, 2024

Cerus Receives FDA Approval for INTERCEPT Blood System for Red Blood Cells for Investigational Use in Phase 3 Study in Puerto Rico

Cerus announced it received U.S. Food and Drug Administration (FDA) approval for an Investigational Device Exemption (IDE) supplement. This allows the use of INTERCEPT-treated red blood cells prepared with a new, second-generation (E2) processing set in a Phase 3 clinical study (ReCePI) in Puerto Rico for chronically transfused sickle cell disease patients....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Cerus Corporation, are just a search away.